Central precocious puberty in a case of late-diagnosed familial testotoxicosis and long-term treatment monitoring
Familial testotoxicosis is a disease with autosomal dominant inheritance that only affects men and which causes gonadotropin-independent precocious puberty. Although basal levels of luteinizing hormone and follicle-stimulating hormone are low, similar to what is expected in the pre-pubertal period, testosterone levels are high. Bicalutamide as an anti-androgen medication and anastrozole as an aromatase inhibitor have been proposed as agents that can be safely used in children. In the present study, we present the case of coexistent familial testotoxicosis and central precocious puberty induced by long-term androgen exposure in a patient aged 7.5 years, whose clinical symptoms started at the age of 4 years. Along with our experience with the effects of long-term (3 years) anastrozole plus bicalutamide treatment in this case, we discuss the relevant literature.
KeywordsFamilial testotoxicosis Anastrazole Bicalutamide
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Written informed consent was obtained from the patient.
- 1.Holland FJ (1991) Gonadotropin-independent precocious puberty. Endocrinol Metab Clin N Am 20:191–210Google Scholar
- 7.Rosenthal SM, Grumbach MM, Kaplan SL (1983) Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxy progesterone acetate therapy in four cases. J Clin Endocrinol Metab 57:571–579CrossRefPubMedGoogle Scholar
- 10.Reiter EO, Mauras N, McCormick K, Kulshreshtha B, Arnrhein J, De Luca F et al (2010) Bicalutamide plus anastrozole for theTreatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). J Pediatr Endocrinol Metab 23:999–1009CrossRefPubMedGoogle Scholar